Perc

Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Results Highlighted in Oral Presentation at International Symposiumof Thrombosis and Haemostasis GENEVA, July 10, 2007 /PRNewswire-FirstCall/ -- BaxterHealthcare Corporation today announced the presentation of findingsfrom the ADAPT (Analysis of Data from ADVATE(R) Prospective Trials)study program database showing a statistically significantrelationship between the duration of time spent...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

- 100 percent of patients treated with VELCADE, cyclophosphamide,and prednisone alive at one year - KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today reported on the presentation of resultsfrom clinical trials of VELCADE based therapies that showed highcomplete remission / complete response(1) (CR) rates in previouslytreated multiple myeloma (MM) p...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

-- 100 percent response rate achieved with VELCADE, lenalidomideand dexamethasone KOS, Greece, June 28 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. (Nasdaq: MLNM) today reported on thepresentation of results from four clinical trials of VELCADE basedtherapies that showed consistently high survival and completeremission / complete response(1) (CR) rates in newly diag...

Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age

New Study Results Show Antibodies Against Cancer-Causing VirusTypes 16 & 18 That Are At Least Ten Times Greater Than NaturalInfection Levels CHICAGO, June 05, 2007 /PRNewswire/ -- New Phase III data showthat at 18 months after the first of a three-dose regimen, 100percent of women up to age 55 vaccinated with the GlaxoSmithKline(GSK) cervical cancer candidate vaccine had antibodies pr...

Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer

ANAHEIM, Calif.--(BUSINESS WIRE)--May 21, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced additional follow-up data on thecompany's Phase 3 investigational therapeutic cancer vaccineOncophage(R) (vitespen). The end-of-study results, which reflect anadditional 17 months' data collection, showed that in a substantialsubset of patients (n = 362) at intermediate risk for diseaserecurrence,...

Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--May 17, 2007 - Resultspublished this week in The Lancet show that Merck's cervical cancervaccine, GARDASIL (Quadrivalent Human Papillomavirus (Types 6, 11,16, 18) Recombinant Vaccine) was 100 percent effective inpreventing high-grade vulvar and vaginal dysplasias caused by HPVtypes 16 and 18, two types strongly associated with these diseases.The 10...

Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients

* Treatment with ISIS 301012 produced at least 45% additionalreduction in patients' LDL-cholesterol when added tomaximally-tolerated lipid-lowering therapies CARLSBAD, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- IsisPharmaceuticals, Inc. announced updated results from its ongoingPhase 2 clinical trial of ISIS 301012 in patients with homozygousfamilial hypercholesterolemia (HoFH), initi...

Waismann Method Survey Reveals 65 Percent of Women Seeking Opiate Dependency Treatment Are Mothers

BEVERLY HILLS, Calif.--(BUSINESS WIRE)--May 10, 2007 - According toThe Waismann Method 2006 Opiate Dependency Survey 65 percent offemale respondents seeking treatment for opiate dependency have oneor more children. Painkillers such as Vicodin, OxyContin, Percocetand Fentanyl were among the drugs cited. In addition, 35 percent ofthe mothers who reported a dependency said they suffered fromde...

Eighty-one Percent of U.S. Adults say that Birth Control Pills and Procedures Should Be Covered by Health Insurance

Support for Medical Use Approval and Insurance Coverage VariesGreatly for Different Medical Treatments ROCHESTER, N.Y. - April 30, 2007-- Most U.S. adults supportapproving the use of medical treatments and procedures that canimpact people's quality of life, including birth controltreatments, in-vitro fertilization, drugs to treat erectiledysfunction and improve memory and to...

Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years

New study results also show evidence of additional protectionagainst infection with other cancer-causing virus types LOS ANGELES, April 17, 2007 /PRNewswire-FirstCall/ -- TheGlaxoSmithKline cervical cancer candidate vaccine, CERVARIX(R),demonstrated 100 percent efficacy in preventing precancerouslesions due to cancer-causing human papillomavirus types 16 and 18for up to 5.5 years in an ex...

Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies

- Combination Therapy Significantly Decreased Tumor Blood VesselDensity and Serum PSA Levels in Prostate Tumors - LOS ANGELES and TUSTIN, Calif., April 17, 2007/PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , aclinical stage biopharmaceutical company developing targetedmonoclonal antibodies for the treatment of cancer and hepatitis Cvirus (HCV) infection, today announced that p...

Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention

BEVERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - InotekPharmaceuticals Corporation announced today the presentation ofpositive Phase 2 clinical data demonstrating the safety of INO-1001as well as the potential for INO-1001 as a preventative agent forcardiac reperfusion injury. The study was conducted in subjectswith acute ST-elevated myocardial infarction (STEMI) undergoingprimary percutaneo...

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients Presented at ACC

* Homozygous FH patients already being treated with maximallytolerated lipid-lowering therapies experienced 50% furtherreductions in LDL-C with similar reductions in other atherogenicwhen treated with 300 mg/week ISIS 301012 NEW ORLEANS, and CARLSBAD, Calif., March 26, 2007/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announcedresults from its ongoing Phase 2 clinical trial of ISIS...